FDA Delays Hand Roche Extra Year of Drug Patent Protection
Published Date: 12/10/2025
Notice
Summary
Hoffman-La Roche just scored a one-year extra patent life for their drug Bitopertin because the FDA’s approval process is still underway. This means the company keeps exclusive rights to sell Bitopertin oral tablets until December 17, 2026, giving them more time to make money before others can copy it. If the FDA takes longer, they can get up to five one-year extensions, so the clock keeps ticking in their favor!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Up to Five One-Year Extensions Possible
Under 35 U.S.C. 156(d)(5), the term of a patent may be extended for no more than five interim periods of up to one year each if the Food and Drug Administration approval phase is expected to extend beyond the patent's expiration. This means the patent owner may seek up to five separate one-year interim extensions if the FDA approval phase continues to delay beyond expiry.
One-Year Patent Extension Granted
The U.S. Patent and Trademark Office granted a one-year interim extension of U.S. Patent No. 7,319,099 for the drug Bitopertin (GlyT1 inhibitor) oral tablets. The patent's original expiration date of December 17, 2025 is extended by one year to December 17, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-08798 — Extension and Modification of the Fast-Track Appeals Pilot Program
The USPTO is extending its Fast-Track Appeals Pilot Program until May 6, 2028, letting inventors speed up their patent appeal reviews. Now, decisions will come even faster—within four months instead of six! This helps inventors get answers quicker without changing fees, making the patent process smoother and snappier.
2026-08101 — Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; DOCX Submission Requirements
The USPTO is asking for public comments on updating their rules about submitting patent applications in DOCX format. If you don’t use DOCX for certain patent filings, you might have to pay a fee starting from January 2024. Comments are open until June 26, 2026, so now’s the time to speak up if you’re affected!
2026-07831 — Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Secrecy and License To Export
The USPTO is asking for your thoughts on renewing a form that helps keep some patent info secret for national security and controls exporting licenses. This affects inventors and businesses dealing with sensitive tech, aiming to keep paperwork light and clear. You’ve got until May 22, 2026, to share your comments—no fees, just your voice!
2026-07574 — Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Patent Trial and Appeal Board (PTAB) Appeals
The Patent and Trademark Office is asking for public feedback on how it collects information for appeals handled by the Patent Trial and Appeal Board (PTAB). This is a routine update to keep things running smoothly and make sure the process is clear and efficient. If you’re involved in patent appeals, now’s your chance to share your thoughts before June 22, 2026!
2026-07575 — Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Global Intellectual Property Academy (GIPA) Surveys
The USPTO is asking for your thoughts on updating their Global Intellectual Property Academy (GIPA) surveys, which help improve how they support IP systems worldwide. If you’re involved in IP or just curious, you can comment until June 22, 2026. This update won’t cost you money but will help make sure the surveys stay useful and clear.
2026-07442 — Termination of the Fast-Track for COVID-19-Related Appeals Pilot Program
The USPTO is ending its Fast-Track program that sped up COVID-19-related patent appeals because it wasn’t used much. Starting April 17, 2026, no new fast-track requests will be accepted, letting the office focus on speeding up all patent appeals instead. This change won’t cost anyone extra but means COVID-19 appeals will follow the regular review timeline from now on.
Previous / Next Documents
Previous: 2025-22422 — Information Collection: Scheduling Information for the Licensing of Accident Tolerant, Higher Burnup, and Increased Enrichment Fuels
The Nuclear Regulatory Commission is renewing its info collection about scheduling licenses for new, safer nuclear fuels that last longer and use more energy. This affects nuclear companies who need to share their plans with the NRC. Comments on this renewal are open until February 9, 2026, with no new costs expected, just smoother licensing updates.
Next: 2025-22425 — Agency Information Collection Activities; Proposed Renewal; Comment Request: Renewal Without Change of Information Collection Requirements in Connection With the Imposition of Special Measures
FinCEN is renewing its paperwork rules tied to special measures against certain risky money laundering groups—without making any changes. Banks and businesses affected by these rules should keep following the same info-sharing steps, and the public can comment until February 9, 2026. This renewal keeps things steady with no new costs or surprises, just a smooth continuation of current requirements.